Please click
here for Neulasta® Reimbursement support information.
For assistance, call the Reimbursement Connection®1-800-272-9376.
Neulasta® (pegfilgrastim) is indicated to decrease the incidence
of infection, as manifested by febrile neutropenia, in patients with nonmyeloid
malignancies receiving myelosuppressive anticancer drugs associated with a clinically
significant incidence of febrile neutropenia.
